Luyan Pharma Co., Ltd. Class A

As of June 30, 2026, Luyan Pharma Co., Ltd. Class A carries a market capitalization of 3.90B, placing it among publicly traded companies globally. Its enterprise value stands at 8.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Luyan Pharma Co., Ltd. Class A has 388.52M shares outstanding.

As of June 30, 2026, Luyan Pharma Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 13.65. The price-to-sales ratio is 0.19, and the price-to-book ratio stands at 1.18.

As of June 30, 2026, Luyan Pharma Co., Ltd. Class A trades at an EV/EBITDA multiple of 22.05 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.40 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 22.05 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 8.54B versus a market cap of 3.90B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Luyan Pharma Co., Ltd. Class A maintains a current ratio of 1.10, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 158.66, indicating elevated leverage, while an interest coverage ratio of 2.28 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Luyan Pharma Co., Ltd. Class A posted a return on equity (ROE) of 8.78, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.32 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 2.23, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.89, useful for judging operating efficiency across full business cycles. The company generates approximately 3.72M in revenue per employee across its workforce of 5,692.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.09 indicates how many times Luyan Pharma Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Luyan Pharma Co., Ltd. Class A recorded 103.72M in income tax expense. That works out to an effective tax rate of 26.75, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 387.73M, leaving 287.43M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Luyan Pharma Co., Ltd. Class A's stock has gained approximately 15.23% over the past 52 weeks. The 50-day moving average sits at 10.90, while the 200-day moving average is 13.57.

Over the twelve months ended June 30, 2026, Luyan Pharma Co., Ltd. Class A generated 21.20B in revenue and converted that into 287.43M in net income, yielding earnings per share of 0.73. EBITDA reached 387.35M, while operating income came in at 591.20M.

As of June 30, 2026, Luyan Pharma Co., Ltd. Class A holds 648.67M in cash and equivalents against 5.28B in total debt, resulting in a net debt position of 4.21B. Total book value stands at 3.31B, with working capital of 967.85M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Luyan Pharma Co., Ltd. Class A posted a gross margin of 7.08, reflecting its pricing power and cost economics. The operating margin of 2.79 and net profit margin of 1.36 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Luyan Pharma Co., Ltd. Class A paid dividends of 0.44 per share. The dividend payout ratio of 61.99 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.75, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Luyan Pharma Co., Ltd. Class A shareholders.

Luyan Pharma Co., Ltd. Class A's most recent stock split took place on September 17, 2020 with a 365:392 split ratio.

As of June 30, 2026, Luyan Pharma Co., Ltd. Class A has an Altman Z-Score of 2.41, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.